Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Therapeutic Advances in Gastroenterology
|
December 15, 2022
First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States
Ke-Xin Sun, Shan-Shan Cao, Feng-Hao Shi, et al.
Plos One
|
August 1, 2012
Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances
Xiao-Qiong Li, Yao-Hong Zhu, Hong-Fu Zhang, et al.
Journal of Neurology
|
January 15, 2025
Peripheral neuropathy in neuronal intranuclear inclusion disease: a clinical and electrophysiological cross-sectional study
Hongfei Tai, Hua Pan, Zaiqiang Zhang, et al.
Cell Research
|
May 20, 2021
The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8
Jia-Yuan Zhang, Bo Zhou, Ru-Yue Sun, et al.
Cell Research
|
July 17, 2023
Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P
Yuan-Li Ai, Wei-Jia Wang, Fan-Jian Liu, et al.
Iliver
|
May 13, 2026
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol
Chao-Man Huang, Shu-Chang Chen, Yi-He Yan, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)
|
June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Therapeutic Advances in Gastroenterology
|
December 15, 2022
First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States
Ke-Xin Sun, Shan-Shan Cao, Feng-Hao Shi, et al.
Plos One
|
August 1, 2012
Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances
Xiao-Qiong Li, Yao-Hong Zhu, Hong-Fu Zhang, et al.
Journal of Neurology
|
January 15, 2025
Peripheral neuropathy in neuronal intranuclear inclusion disease: a clinical and electrophysiological cross-sectional study
Hongfei Tai, Hua Pan, Zaiqiang Zhang, et al.
Cell Research
|
May 20, 2021
The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8
Jia-Yuan Zhang, Bo Zhou, Ru-Yue Sun, et al.
Cell Research
|
July 17, 2023
Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P
Yuan-Li Ai, Wei-Jia Wang, Fan-Jian Liu, et al.
Iliver
|
May 13, 2026
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol
Chao-Man Huang, Shu-Chang Chen, Yi-He Yan, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)
|
June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Page
of 9